Brad L Pohlman

Author PubWeight™ 6.18^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.	J Clin Oncol	2002	3.30
2	Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.	Leuk Lymphoma	2014	1.40
3	Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.	Clin Cancer Res	2012	0.92
4	High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma.	Leuk Lymphoma	2009	0.81